Melanoma vaccine - Progenics

Drug Profile

Melanoma vaccine - Progenics

Alternative Names: BMS 248479; GMK vaccine; MGV vaccine

Latest Information Update: 21 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Class Cancer vaccines
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Malignant melanoma

Most Recent Events

  • 09 Aug 2007 Discontinued - Phase-III for Malignant melanoma in USA, New Zealand, United Kingdom, South America, Europe, South Africa, Australia (SC)
  • 01 Dec 2005 The GMK vaccine is still in active development
  • 21 May 2001 The licence with Bristol-Myers Squibb has been terminated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top